Last 46 quarters of trend data · Healthcare · Medical - Diagnostics & Research
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -95.37 | — | — | — | — | — | — | — | — | — | 3966.28 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 6.16 | 5.48 | 3.04 | 3.09 | 2.86 | 3.65 | 4.44 | 2.78 | 4.94 | 5.18 | 5.00 | 6.80 | 5.02 | 3.97 | 2.75 | 3.33 | 6.27 | 7.08 | 8.99 | 12.26 | 13.88 |
| — | +50.3% | -31.5% | +11.1% | -42.1% | -29.6% | -11.1% | -59.1% | -1.7% | +30.4% | +81.8% | +104.2% | -19.8% | -43.9% | -69.4% | -72.8% | -54.9% | -36.3% | -4.1% | +1.3% | +124.8% | |
| P/B Ratio | 8.24 | 8.03 | 4.14 | 4.07 | 3.37 | 4.33 | 3.92 | 2.44 | 4.02 | 4.26 | 4.02 | 5.54 | 3.96 | 2.89 | 1.85 | 2.16 | 3.74 | 3.96 | 4.75 | 5.99 | 6.12 |
| — | +85.2% | +5.6% | +66.6% | -16.1% | +1.7% | -2.5% | -55.9% | +1.5% | +47.6% | +117.5% | +155.7% | +5.8% | -27.1% | -61.0% | -63.9% | -38.8% | -57.3% | -27.5% | +15.6% | +80.7% | |
| P/FCF | 56.10 | 40.00 | 13.62 | 53.77 | — | 242.22 | 27.96 | 27.34 | — | 96.81 | — | 64.39 | — | — | — | — | — | — | — | 338.32 | — |
| — | -83.5% | -51.3% | +96.6% | — | +150.2% | — | -57.5% | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | 99.72 | 56.00 | — | — | 240.07 | 93.66 | — | — | 61.44 | — | — | — | — | — | — | — | — | — | — |
| — | — | -58.5% | -40.2% | — | — | +290.8% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | 478.73 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.7% | 70.1% | 68.6% | 69.3% | 70.8% | 60.2% | 69.4% | 69.8% | 70.0% | 73.4% | 73.2% | 74.8% | 74.0% | 73.4% | 71.7% | 72.3% | 72.3% | 74.9% | 74.6% | 73.8% | 72.6% |
| — | +16.5% | -1.0% | -0.7% | +1.2% | -18.1% | -5.2% | -6.6% | -5.3% | +0.1% | +2.0% | +3.4% | +2.3% | -2.0% | -3.9% | -2.0% | -0.4% | -4.8% | -2.7% | +3.9% | -5.1% | |
| Operating Margin | -6.4% | -9.4% | -3.0% | -0.3% | -13.6% | -122.8% | -5.6% | -3.8% | -16.7% | -10.5% | 1.1% | -12.4% | -12.8% | -21.5% | -26.4% | -30.6% | -36.4% | -46.7% | -35.5% | -39.5% | -74.7% |
| — | +92.3% | +46.0% | +92.9% | +18.8% | -1071.3% | -610.1% | +69.6% | -30.8% | +51.2% | +104.1% | +59.6% | +64.8% | +54.0% | +25.7% | +22.5% | +51.3% | +47.5% | +28.7% | -58.4% | -215.6% | |
| Net Margin | -6.4% | -9.8% | -2.3% | -0.1% | -14.3% | -121.2% | -5.4% | -2.3% | -17.3% | -7.7% | 0.1% | -13.0% | -12.3% | -23.1% | -28.4% | -31.8% | -37.2% | -46.6% | -36.6% | -40.7% | -7.8% |
| — | +91.9% | +57.3% | +93.5% | +17.2% | -1475.3% | -4368.7% | +82.6% | -40.5% | +66.7% | +100.4% | +59.1% | +66.9% | +50.4% | +22.3% | +21.8% | -379.8% | +50.3% | +26.2% | -60.7% | +80.0% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -8.7% | -3.5% | -0.8% | -0.0% | -4.2% | -30.8% | -1.2% | -0.5% | -3.5% | -1.6% | 0.0% | -2.7% | -2.4% | -4.2% | -4.7% | -5.1% | -5.4% | -6.4% | -4.8% | -4.9% | -1.1% |
| — | +88.6% | +34.0% | +90.3% | -20.1% | -1839.7% | -4747.1% | +81.1% | -44.5% | +61.8% | +100.5% | +48.4% | +55.4% | +35.6% | +1.0% | -4.6% | -414.1% | +66.3% | +43.0% | -82.0% | +81.0% | |
| ROA | -3.5% | -1.5% | -0.3% | -0.0% | -1.7% | -13.6% | -0.6% | -0.2% | -1.7% | -0.8% | 0.0% | -1.3% | -1.2% | -2.0% | -2.3% | -2.6% | -2.7% | -3.3% | -2.5% | -2.6% | -0.5% |
| — | +89.3% | +41.2% | +91.5% | -1.4% | -1666.9% | -4695.2% | +81.1% | -45.0% | +62.1% | +100.5% | +50.2% | +56.9% | +38.4% | +6.4% | +2.3% | -413.8% | +64.9% | +45.6% | -72.4% | +84.2% | |
| ROIC | -3.6% | -1.5% | -0.4% | -0.0% | -1.6% | -13.2% | -0.5% | -0.4% | -1.5% | -1.0% | 0.1% | -1.1% | -1.1% | -1.7% | -1.9% | -2.2% | -2.4% | -3.0% | -2.2% | -2.5% | -5.6% |
| — | +88.6% | +18.4% | +90.1% | -2.9% | -1223.9% | -638.0% | +67.6% | -38.6% | +40.8% | +105.3% | +48.6% | +54.5% | +44.0% | +11.8% | +10.4% | +56.8% | +69.4% | +51.8% | -71.0% | -199.9% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.05 | 1.05 | 1.01 | 1.02 | 1.05 | 1.15 | 0.86 | 0.87 | 0.82 | 0.81 | 0.82 | 0.84 | 0.84 | 0.80 | 0.79 | 0.76 | 0.73 | 0.70 | 0.69 | 0.67 | 0.65 |
| — | -8.4% | +18.0% | +18.0% | +29.0% | +41.2% | +4.7% | +3.3% | -2.8% | +1.0% | +4.3% | +9.9% | +14.7% | +14.3% | +14.1% | +13.9% | +12.5% | -32.6% | -6.0% | -0.9% | -1.0% | |
| Debt / EBITDA | — | — | 83.56 | 47.45 | — | — | 179.49 | 103.27 | — | — | 43.34 | — | — | — | — | — | — | — | — | — | — |
| — | — | -53.4% | -54.1% | — | — | +314.1% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.43 | 2.23 | 2.72 | 2.89 | 2.73 | 2.15 | 2.12 | 2.17 | 1.64 | 2.32 | 2.41 | 2.41 | 2.97 | 2.38 | 2.47 | 2.48 | 2.53 | 2.76 | 2.27 | 2.47 | 2.82 |
| — | +3.9% | +28.5% | +33.0% | +66.8% | -7.5% | -12.1% | -9.7% | -45.0% | -2.5% | -2.6% | -3.2% | +17.6% | -13.7% | +8.8% | +0.6% | -10.5% | -20.6% | -64.2% | -63.5% | -53.7% | |
| Quick Ratio | 2.17 | 1.97 | 2.44 | 2.56 | 2.38 | 1.92 | 1.93 | 1.98 | 1.45 | 2.07 | 2.13 | 2.14 | 2.63 | 2.09 | 2.20 | 2.23 | 2.29 | 2.56 | 2.14 | 2.34 | 2.68 |
| — | +2.4% | +26.5% | +29.2% | +64.1% | -7.2% | -9.5% | -7.3% | -45.0% | -1.0% | -3.3% | -3.9% | +14.9% | -18.1% | +3.0% | -4.8% | -14.5% | -23.2% | -64.5% | -63.5% | -53.8% | |
| Interest Coverage | — | — | -2.61 | -0.22 | -10.89 | -106.28 | -4.76 | — | -13.43 | -8.63 | 0.87 | -9.84 | — | -21.97 | -26.37 | -35.38 | -39.52 | -47.54 | -34.62 | -36.90 | -65.11 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 46 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying EXAS stock.
Exact Sciences Corporation's current P/E is -95.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Exact Sciences Corporation's current operating margin is -6.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Exact Sciences Corporation's business trajectory between earnings reports.